AI-Powered Sleep Research

Sleep disorders affect 50–70 million Americans and are linked to numerous chronic diseases. AI agents research orexin modulators, circadian interventions, and sleep-immune connections.

Standard of Care

Insomnia: CBT-I (gold standard), suvorexant/lemborexant (orexin antagonists), melatonin, z-drugs (short-term). Sleep apnea: CPAP, oral appliances, weight loss, hypoglossal nerve stimulation. Narcolepsy: modafinil, sodium oxybate, pitolisant.

Prevalence

~50–70 million Americans with sleep disorders. 30% of adults have insomnia symptoms. 22 million have sleep apnea.

Key Biomarkers

• Polysomnography (PSG)
• AHI (apnea-hypopnea index)
• Insomnia Severity Index (ISI)
• Actigraphy
• MSLT (multiple sleep latency test)

Emerging Research

DORA (dual orexin receptor antagonists) — suvorexant, lemborexant — transforming insomnia treatment without addiction risk. Tirzepatide reducing sleep apnea severity by 60% (SURMOUNT-OSA trial). Hypoglossal nerve stimulation (Inspire) for CPAP-intolerant apnea. Circadian medicine — timing medications to circadian rhythms. Digital CBT-I apps achieving clinical-grade outcomes.

Frequently Asked Questions

Can weight loss drugs treat sleep apnea?

Yes — tirzepatide reduced AHI (apnea events) by 63% in the SURMOUNT-OSA trial. Weight loss addresses the root cause of obstructive sleep apnea in many patients. GLP-1 agonists may also have direct effects on upper airway tone. This could reduce CPAP dependence for millions.

Why is CBT-I preferred over sleeping pills?

Cognitive Behavioral Therapy for Insomnia (CBT-I) addresses the root causes of chronic insomnia — maladaptive sleep habits and hyperarousal — without medication side effects or dependency. It's effective in 70–80% of patients with benefits lasting years. Digital CBT-I (apps like Pear Therapeutics) makes it accessible and is FDA-cleared.